期刊
EMERGING MICROBES & INFECTIONS
卷 9, 期 1, 页码 1497-1505出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2020.1780951
关键词
SARS; COVID-19; SARS-CoV-2; antibody; serology
资金
- Singapore Singapore Medical Research Council (NMRC) [STPRG-FY19-001, COVID19RF-003]
- Singapore National Research Foundation (NRF) [NRF2016NRF-NSFC002-013]
In response to the coronavirus disease 2019 (COVID-19) outbreak, caused by SARS-CoV-2, multiple diagnostic tests are required for acute disease diagnosis, contact tracing, monitoring asymptomatic infection rates and assessing herd immunity. While PCR remains the frontline test of choice in the acute diagnostic setting, serological tests are urgently needed. Unlike PCR tests which are highly specific, cross-reactivity is a major challenge for COVID-19 antibody tests considering there are six other coronaviruses known to infect humans. SARS-CoV is genetically related to SARS-CoV-2 sharing approximately 80% sequence identity and both belong to the speciesSARS related coronavirusin the genusBetacoronavirusof familyCoronaviridae. We developed and compared the performance of four different serological tests to comprehensively assess the cross-reactivity between COVID-19 and SARS patient sera. There is significant cross-reactivity when N protein of either virus is used. The S1 or RBD regions from the spike (S) protein offers better specificity. Amongst the different platforms, capture ELISA performed best. We found that SARS survivors all have significant levels of antibodies remaining in their blood 17 years after infection. Anti-N antibodies waned more than anti-RBD antibodies, and the latter is known to play a more important role in providing protective immunity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据